Cellectar Biosciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Cellectar Biosciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cellectar Biosciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cellectar Biosciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Cellectar Biosciences Inc (Cellectar) is dedicated to discovering, developing, and commercializing innovative cancer treatments. The company utilizes its proprietary phospholipid ether drug conjugate (PDC) delivery platform to develop targeted cancer therapies. Cellectar’s PDC platform employs a unique approach by exploiting specific changes in tumor cell membranes and metabolic pathways prevalent in cancer cells. This method ensures the selective and efficient delivery of therapeutic payloads directly to tumor cells, thereby improving treatment effectiveness and minimizing off-target impacts.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Cellectar's primary research and development initiatives focus on leveraging its proprietary phospholipid ether drug conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, aiming to improve efficacy and safety by reducing off-target effects. The company is primarily focused on developing its radioconjugate PDC programs, known as phospholipid radioconjugates (PRCs), which are designed to deliver a radioisotope directly to cancer cells while minimizing exposure to healthy cells. Cellectar has established a collaboration outsourcing model to utilize third-party expertise, accelerate project timelines, improve productivity, and limit costs. The company plans to develop PDCs both independently and through research and development collaborations to generate near-term capital, supplement internal resources, gain access to novel molecules or payloads, accelerate product candidate development, and broaden its proprietary and partnered product pipelines. In FY2024, the company spent US$26.1 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer